ATE61227T1 - Menschliche komplementfaktoren und ihre therapeutische verwendung. - Google Patents

Menschliche komplementfaktoren und ihre therapeutische verwendung.

Info

Publication number
ATE61227T1
ATE61227T1 AT86308738T AT86308738T ATE61227T1 AT E61227 T1 ATE61227 T1 AT E61227T1 AT 86308738 T AT86308738 T AT 86308738T AT 86308738 T AT86308738 T AT 86308738T AT E61227 T1 ATE61227 T1 AT E61227T1
Authority
AT
Austria
Prior art keywords
therapeutic use
human complement
complement factors
factor
saline
Prior art date
Application number
AT86308738T
Other languages
English (en)
Inventor
Isao Sankyo Bio-Science Kaneko
Shinagawa-Ku
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Application granted granted Critical
Publication of ATE61227T1 publication Critical patent/ATE61227T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y10S530/831—Cohn fractions
AT86308738T 1985-11-08 1986-11-10 Menschliche komplementfaktoren und ihre therapeutische verwendung. ATE61227T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP25018785 1985-11-08
EP86308738A EP0222611B1 (de) 1985-11-08 1986-11-10 Menschliche Komplementfaktoren und ihre therapeutische Verwendung

Publications (1)

Publication Number Publication Date
ATE61227T1 true ATE61227T1 (de) 1991-03-15

Family

ID=17204104

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86308738T ATE61227T1 (de) 1985-11-08 1986-11-10 Menschliche komplementfaktoren und ihre therapeutische verwendung.

Country Status (6)

Country Link
US (1) US4883784A (de)
EP (1) EP0222611B1 (de)
JP (1) JPH0742235B2 (de)
AT (1) ATE61227T1 (de)
CA (1) CA1294872C (de)
DE (1) DE3677897D1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1335792C (en) * 1987-08-18 1995-06-06 Chaim O. Jacob Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
US5256642A (en) * 1988-04-01 1993-10-26 The Johns Hopkins University Compositions of soluble complement receptor 1 (CR1) and a thrombolytic agent, and the methods of use thereof
EP0360191A3 (de) * 1988-09-19 1991-05-08 Daiichi Pharmaceutical Co., Ltd. Anti-Aidsvirus-Mittel
DK708488D0 (da) * 1988-12-20 1988-12-20 Nordisk Gentofte Faktor i praeparat
US5264549A (en) * 1989-09-12 1993-11-23 The Beth Israel Hospital Association Characterization and method of isolation of factor J, an inhibitor of complement C1
US5109114A (en) * 1989-09-12 1992-04-28 Beth Israel Hospital Characterization and method of isolation for an inhibitor of complement C1
US5268363A (en) * 1989-09-12 1993-12-07 The Beth Israel Hospital Association Method of treatment to inhibit the undesirable activation of the complement cascade with factor J, an inhibitor of complement C1
AU654116B2 (en) * 1989-10-12 1994-10-27 Imutran Limited Modified biological material
US6458360B1 (en) 1990-04-25 2002-10-01 The Johns Hopkins University Soluble complement regulatory molecules
EP0512733A2 (de) * 1991-05-03 1992-11-11 Washington University Modifizierter Komplementsystemregler
DE4222534A1 (de) * 1992-07-09 1994-01-13 Behringwerke Ag Verwendung von Komplement-Inhibitoren zur Herstellung eines Arzneimittels zur Prophylaxe und Therapie von entzündlichen Darm- und Hauterkrankungen sowie Purpura
DE69433745T2 (de) * 1993-09-24 2005-05-19 Washington University Modifizierte, verkürzte regulatoren des komplementsystems
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
US6066319A (en) * 1996-04-30 2000-05-23 President And Fellows Of Harvard College Drug delivery using terminal complement components
US6017703A (en) * 1997-03-06 2000-01-25 Bard Diagnostic Sciences, Inc. Methods and compositions for screening for or modulating a tumor associated antigen
ES2254220T3 (es) * 1999-09-10 2006-06-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Determinacion de proteinas de enlace con la adrnomedulina.
US6820011B2 (en) * 2001-04-11 2004-11-16 The Regents Of The University Of Colorado Three-dimensional structure of complement receptor type 2 and uses thereof
EP1569685B8 (de) 2002-11-15 2012-12-05 MUSC Foundation For Research Development Komplement-modulatoren für komplement-rezeptor 2
ES2432112T3 (es) * 2004-02-10 2013-11-29 The Regents Of The University Of Colorado, A Body Corporate Inhibición del factor B, de la vía alternativa del complemento y métodos relacionados
CA2597411C (en) 2005-02-14 2014-08-12 University Of Iowa Research Foundation Use of complement factor h polymorphisms in treatment and diagnosis of age-related macular degeneration
AU2006249835B2 (en) * 2005-05-26 2011-09-08 Musc Foundation For Research Development Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
WO2007038995A1 (en) * 2005-09-19 2007-04-12 Csl Behring Gmbh Factor h for the treatment of chronic nephropathies and production thereof
FR2894145B1 (fr) * 2005-12-07 2008-10-17 Lab Francais Du Fractionnement Utilisation de facteur h du complement a titre de medicament
ES2523640T3 (es) 2006-06-21 2014-11-28 Musc Foundation For Research Development Direccionamiento del factor H del complemento para el tratamiento de enfermedades
ES2507542T3 (es) * 2007-03-14 2014-10-15 Alexion Cambridge Corporation Anticuerpo anti-factor B humanizado
ES2595059T3 (es) * 2007-03-20 2016-12-27 Csl Behring Gmbh Métodos para la producción a escala industrial de preparados terapéuticos del Factor H del complemento a partir de plasma humano
GB0904427D0 (en) * 2009-03-13 2009-04-29 Lachmann Peter Treatment of diseases related to hyperactivity of the complement system
CA2767105A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
AT516600B1 (de) 2009-07-23 2016-07-15 Baxter Int Herstellung von faktor h (fh) und fh-derivaten aus plasma
CA2795311A1 (en) 2009-11-05 2011-05-12 Taligen Therapeutics, Inc. Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
FR2952640B1 (fr) * 2009-11-16 2012-12-07 Lab Francais Du Fractionnement Procede de fabrication d'une preparation de facteur h
FR2952539B1 (fr) * 2009-11-16 2012-01-13 Lab Francais Du Fractionnement Preparation d'un concentre de facteur h
US20130011857A1 (en) 2010-02-12 2013-01-10 Cemm Forschungszentrum Fur Molekulare Medizin Gmbh Complement factor h for oxidative stress disease conditions
EP2569332B1 (de) 2010-05-14 2019-01-09 The Regents of the University of Colorado, A Body Corporate Verbesserte komplement-rezeptor-2-anzielungsgruppen
US8772462B2 (en) 2010-05-26 2014-07-08 Baxter International Inc. Removal of serine proteases by treatment with finely divided silicon dioxide
AU2010202125B1 (en) 2010-05-26 2010-09-02 Takeda Pharmaceutical Company Limited A method to produce an immunoglobulin preparation with improved yield
US8796430B2 (en) 2010-05-26 2014-08-05 Baxter International Inc. Method to produce an immunoglobulin preparation with improved yield
SG186397A1 (en) 2010-06-22 2013-01-30 Univ Colorado Regents Antibodies to the c3d fragment of complement component 3
FR2967071A1 (fr) * 2010-11-10 2012-05-11 Lab Francais Du Fractionnement Facteur h pour le traitement de maladies auto-immunes du systeme nerveux
EP2557089A2 (de) * 2011-07-15 2013-02-13 Fundació Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Zusammensetzungen und Verfahren zur Immunmodulation
WO2013177035A2 (en) 2012-05-24 2013-11-28 Alexion Pharmaceuticals, Inc. Humaneered anti-factor b antibody
WO2014028865A1 (en) 2012-08-17 2014-02-20 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
CA2908597A1 (en) * 2013-03-14 2014-09-25 Baxalta Incorporated Factor h for treatment of rheumatoid arthritis
AU2013203048A1 (en) 2013-03-15 2014-10-02 Baxalta GmbH Isolation of factor h from fraction i paste
AU2013202965B2 (en) 2013-03-15 2016-07-21 Takeda Pharmaceutical Company Limited Improved method for producing factor h from a plasma precipitation fraction
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2933015A1 (de) * 1979-08-16 1981-03-26 Behringwerke AG, 35041 Marburg Verfahren zur herstellung der dritten komponente des komplements aus menschlichem blutplasma
US4444757A (en) * 1981-11-16 1984-04-24 Research Corporation Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
DE3228502A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
US4618494A (en) * 1984-07-20 1986-10-21 Immunology Development Corporation Human Immune Factors and processes for their production and use

Also Published As

Publication number Publication date
JPH0742235B2 (ja) 1995-05-10
CA1294872C (en) 1992-01-28
EP0222611A3 (en) 1988-04-06
US4883784A (en) 1989-11-28
DE3677897D1 (de) 1991-04-11
JPS62201822A (ja) 1987-09-05
EP0222611A2 (de) 1987-05-20
EP0222611B1 (de) 1991-03-06

Similar Documents

Publication Publication Date Title
ATE61227T1 (de) Menschliche komplementfaktoren und ihre therapeutische verwendung.
Nutton From Galen to Alexander, aspects of medicine and medical practice in late antiquity
ES2001996A6 (es) Procedimiento para preparar composiciones farmaceuticas contra enfermedades cronicas de trasplante frente a hospedante y contra enfermedades de autoinmunidad.
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
SE8300623D0 (sv) Farmaceutisk komposition innehallande stabil mikrokristallin cis-platina(ii)-diammindiklorid (cisplatin)
MX9203543A (es) Medicamento.
IL102848A0 (en) Polypeptides having growth hormone releasing activity,their use and pharmaceutical compositions containing them
ATE74510T1 (de) Adoptivimmuntherapie als behandlungsmodalitaet bei menschen.
FI103180B1 (fi) Flurbiprofeenia sisältävien lääkkeiden valmistus kipujen ja/tai tulehdusten torjumiseksi eläimissä ja ihmisissä
LV10878A (lv) Adas apstradasana ar izveletiem amfifiliem kopolimeriem
DE68910159D1 (de) Dosierform für Verabreichung in der Humanmedizin.
SE8903914D0 (sv) Oral composition for the treatment of inflammatory bowel diseases
PL328003A1 (en) Modulation of cytokin th 1/th 2 expression by means of ribavirin and ribavirin analoques in t lymphocytes
ATE81984T1 (de) Verwendung von granulozyt-makrophagen-kolonie erregenden faktor zur herstellung eines medikaments zur behandlung von bakterieller krankheiten.
EP0079556A3 (de) Morphinanderivate, ihre Herstellung, sowie diese enthaltende Arzeimittel
IT1255723B (it) Uso di paratormone,suoi frammenti biologicamente attivi e peptidi correlati, per la preparazione di composizioni farmaceutiche utili nella prevenzione e terapia dell'aborto e del parto pretermine ed in generale per il trattamento della gestazione
KR910700069A (ko) Gm-csf를 사용한 백혈구 기능장애의 치료
ES2061496T3 (es) Tratamiento intralesional del carcinoma de celulas basales con alfa-interferon humano recombinante.
OA08768A (fr) Traitement du virus su SIDA par l'interféron alpha humain recombinant.
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
KR900701301A (ko) 후천성 면역 결핍증과 연관된 골수억제증의 치료방법
KR870005642A (ko) 디플루니살과 트로메타민의 혼합물
Hamilton et al. 2, 4, 6-TRIHYDROXYBENZOIC ACIDIN THE TREATMENT OF RHEUMATIC FEVER
Padovani et al. Clinical efficacy and tolerance of ceftazidime as sole antibiotic in neonatal bacterial infections.
Juca et al. Antimicrobial therapy with cefoxitin sodium in vascular surgery and angiology: Clinical and laboratorial survey.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee